Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2011, Article ID 376092, 5 pages
http://dx.doi.org/10.1155/2011/376092
Review Article

Enzymatically Modified Low-Density Lipoprotein Is Recognized by C1q and Activates the Classical Complement Pathway

1Laboratoire d'Enzymologie Moléculaire, Institut de Biologie Structurale Jean-Pierre Ebel, 41 rue Jules Horowitz, 38027 Grenoble Cedex 1, France
2Laboratoire de Microscopie Electronique Structurale, Institut de Biologie Structurale Jean-Pierre Ebel, 41 rue Jules Horowitz, 38027 Grenoble Cedex 1, France

Received 21 October 2010; Accepted 18 December 2010

Academic Editor: Robert Salomon

Copyright © 2011 Gérard J. Arlaud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. Steinberg, “Low density lipoprotein oxidation and its pathobiological significance,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 20963–20966, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Bhakdi, B. Dorweiler, R. Kirchmann et al., “On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety,” Journal of Experimental Medicine, vol. 182, no. 6, pp. 1959–1971, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Torzewski, P. Suriyaphol, K. Paprotka et al., “Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2130–2136, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. Steinberg, S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum, “Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity,” New England Journal of Medicine, vol. 320, no. 14, pp. 915–924, 1989. View at Google Scholar · View at Scopus
  6. E. Wieland, S. Parthasarathy, and D. Steinberg, “Peroxidase-dependent metal-independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation?” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 5929–5933, 1993. View at Google Scholar · View at Scopus
  7. F. F. Chao, L. M. Amende, E. J. Blanchette-Mackie et al., “Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas,” American Journal of Pathology, vol. 131, no. 1, pp. 73–83, 1988. View at Google Scholar · View at Scopus
  8. F. F. Chao, E. J. Blanchette-Mackie, V. V. Tertov, S. I. Skarlatos, Y. J. Chen, and H. S. Kruth, “Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome,” Journal of Biological Chemistry, vol. 267, no. 7, pp. 4992–4998, 1992. View at Google Scholar · View at Scopus
  9. M. Torzewski and K. J. Lackner, “Initiation and progression of atherosclerosis—enzymatic or oxidative modification of low-density lipoprotein?” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 12, pp. 1389–1394, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. O. Haskard, J. J. Boyle, and J. C. Mason, “The role of complement in atherosclerosis,” Current Opinion in Lipidology, vol. 19, no. 5, pp. 478–482, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. P. S. Seifert, F. Hugo, J. Tranum-Jensen, U. Zahringer, M. Muhly, and S. Bhakdi, “Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions,” Journal of Experimental Medicine, vol. 172, no. 2, pp. 547–557, 1990. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Bhakdi, M. Torzewski, K. Paprotka et al., “Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence,” Circulation, vol. 109, no. 15, pp. 1870–1876, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. Gaboriaud, N. M. Thielens, L. A. Gregory, V. Rossi, J. C. Fontecilla-Camps, and G. J. Arlaud, “Structure and activation of the C1 complex of complement: unraveling the puzzle,” Trends in Immunology, vol. 25, no. 7, pp. 368–373, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Biró, N. M. Thielens, L. Cervenák, Z. Prohászka, G. Füst, and G. J. Arlaud, “Modified low density lipoproteins differentially bind and activate the C1 complex of complement,” Molecular Immunology, vol. 44, no. 6, pp. 1169–1177, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Biro, W. L. Ling, and G. J. Arlaud, “Complement protein c1q recognizes enzymatically modified low-density lipoprotein through unesterified fatty acids generated by cholesterol esterase,” Biochemistry, vol. 49, no. 10, pp. 2167–2176, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. P. Tacnet-Delorme, S. Chevallier, and G. J. Arlaud, “β-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for Aβ on the C1q globular regions,” Journal of Immunology, vol. 167, no. 11, pp. 6374–6381, 2001. View at Google Scholar · View at Scopus
  17. R. J. Ziccardi, “A new role for C1-inhibitor in homeostasis: control of activation of the first component of human complement,” Journal of Immunology, vol. 128, no. 6, pp. 2505–2508, 1982. View at Google Scholar · View at Scopus
  18. V. Garlatti, A. Chouquet, T. Lunardi et al., “Cutting edge: C1q binds deoxyribose and heparan sulfate through neighboring sites of its recognition domain,” Journal of Immunology, vol. 185, no. 2, pp. 808–812, 2010. View at Publisher · View at Google Scholar · View at PubMed
  19. M. O. Pentikäinen, E. M. P. Lehtonen, and P. T. Kovanen, “Aggregation and fusion of modified low density lipoprotein,” Journal of Lipid Research, vol. 37, no. 12, pp. 2638–2649, 1996. View at Google Scholar · View at Scopus
  20. K. Oorni, M. O. Pentikainen, M. Ala-Korpela, and P. T. Kovanen, “Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions,” Journal of Lipid Research, vol. 41, no. 11, pp. 1703–1714, 2000. View at Google Scholar · View at Scopus
  21. H. V. Kothari, M. J. Bonner, and B. F. Miller, “Cholesterol ester hydrolase in homogenates and lysosomal fractions of human aorta,” Biochimica et Biophysica Acta, vol. 202, no. 2, pp. 325–331, 1970. View at Google Scholar · View at Scopus
  22. N. Simionescu, E. Vasile, F. Lupu et al., “Prelesional events in atherogenesis: accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit,” American Journal of Pathology, vol. 123, no. 1, pp. 109–125, 1986. View at Google Scholar · View at Scopus
  23. U. Kishore, C. Gaboriaud, P. Waters et al., “C1q and tumor necrosis factor superfamily: modularity and versatility,” Trends in Immunology, vol. 25, no. 10, pp. 551–561, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. N. R. Cooper, “The classical complement pathway: activation and regulation of the first complement component,” Advances in Immunology, vol. 37, pp. 151–216, 1985. View at Google Scholar · View at Scopus
  25. D. A. Fraser and A. J. Tenner, “Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages,” Journal of Immunology, vol. 185, no. 7, pp. 3932–3939, 2010. View at Publisher · View at Google Scholar · View at PubMed
  26. J. Faro, Y. Chen, P. Jhaveri et al., “L-Ficolin binding and lectin pathway activation by acetylated low-density lipoprotein,” Clinical and Experimental Immunology, vol. 151, no. 2, pp. 275–283, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus